ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1

Diabetes Care

Volumn 26, Issue 8, 2003, Pages 2421-2425

  Amann, Berthold ^a,b   Tinzmann, Ralph ^c   Angelkort, Bernhard ^c  

^a Hospital Kamilianer   (Germany)

^b Franziskus Hospital Berlin   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; LISINOPRIL; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; EXTRACELLULAR MATRIX; FEMALE; GLUCOSE METABOLISM; HUMAN; KIDNEY FUNCTION; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION, RENAL; KIDNEY; LISINOPRIL; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 0042524595     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.8.2421     Document Type: Article

References (35)

1. Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127-1133, 1999
2. Ziyadeh FN, Goldfarb S: The renal tubulointerstitium in diabetes mellitus. Kidney Int 39:464-475, 1991
3. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935-944, 1995
4. Rovin BH, Phan LT: Chemotactic factors and renal inflammation. Am J Kidney Dis 31:1065-1084, 1998
5. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480-485, 1993
6. Gu L, Tseng SC, Rollins BJ: Monocyte chemoattractant protein-1. Chem Immunol 72:7-29, 1999
7. Prodjosadj W, Gerritsma JS, Van Es LA, Daha MR, Bruijn JA: Monocyte chemoattractant protein-1 in normal and diseased kidneys: an immunohistochemical analysis. Clin Nephrol 44:148-55, 1995
8. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684-690, 2000
9. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H: A high glucose concentration stimulates the expression of monocyte chemotactic peptide-1 in human mesangial cells. Nephron 79:33-37, 1998
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
11. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus: a 7-year follow-up study. Arch Int Med 156:286-289, 1996
12. Anderson S, Jung FF, Ingelfinger JR: Renin-angiotensin system in diabetic rats: functional, immunohistochemical and molecular biologic correlations. Am J Physiol 265:477-486, 1993
13. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G: Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 4:19-25, 1996
14. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM: Angiotensin II induces monocyte chemoattractant proteine-1 gene expression in rat vascular smooth muscle cells. Circ Res 83:952-959, 1998
15. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430-439, 1998
16. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H: Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58:1492-1499, 2000
17. Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease, with emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl. 2):64-78, 1983
18. Kato S, Luyckx VA, Ots M, Lee KW, Ziai F, Troy JL, Brenner BM, MacKenzie HS: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56:1037-1048, 1999
19. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
20. Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 16:1-4, 2002
21. Ihm CG: Monocyte chemotactic peptide-1 in diabetic nephropathy. Kidney Int 52:S20-22, 1997
22. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
23. Chen S, Wolf G, Ziyadeh FN: The renin-angiotensin system in diabetic nephropathy. Contrib Nephrol 135:212-221, 2001
24. Poon M, Hsu WC, Bogdanov VY, Taubman MB: Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Pathol 149:307-317, 1996
25. Goetzel EJ, Klickstein LB, Watt KWK, Weintroub BU: The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun 97:1097-1102, 1980
26. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T: Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 17:537-545, 1999
27. Wolf G, Schneider A, Helmchen U, Stahl RA: AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 6:112-120, 1998
28. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, Fukamizu A, Murakami K: Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103:627-635, 1999
29. El-Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O: Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 29:55-62, 1997
30. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA: Production and cytokine mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48:1477-1486, 1995
31. Gonzalez-Cuadrado S, Bustos C, Ruiz-Ortega M, Ortiz A, Guijarro C, Plaza JJ, Egido J: Expression of leukocyte chemoattractants by interstitial renal fibroblasts: up-regulation by drugs associated with interstitial fibrosis. Clin Exp Immunol 106:518-522, 1996
32. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DCH: Induction of MCP-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 8:1537-1545, 1997
33. Wang Y, Rangan GK, Tay Y-C, Wang Y, Harris DCH: Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor κB in proximal tubule cells. J Am Soc Nephrol 10:1204-1213, 1999
34. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-194, 1998
35. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J: Atorvastatin reduces NF-κb activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147:253-261, 1999